The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer
Open accessAbstract
Purpose: The identification of a molecular signature predicting the relapse of tamoxifen-treated primary breast cancers should help the therapeutic management of estrogen receptor–positive cancers. Experimental Design: A series of 132 primary tumors from patients who received adjuvant tamoxifen were analyzed for expression profiles at the whole-genome level by 70-mer oligonucleotide microarrays. A supervised analysis was done to identify an expression signature. Results: We defined a 36-gene signature that correctly classified 78% of patients with relapse and 80% of relapse-free patients (79% accuracy). Using 23 independent tumors, we confirmed the accuracy of the signature (78%) whose relevance was further shown by using published microarray data from 60 tamoxifen-treated patients (63% accuracy). Univariate analysis using the validation set of 83 tumors showed that the 36-gene classifier is more efficient in predicting disease-free survival than the traditional histopathologic prognostic factors and is as effective as the Nottingham Prognostic Index or the “Adjuvant!” software. Multivariate analysis showed that the molecular signature is the only independent prognostic factor. A comparison with several already published signatures demonstrated that the 36-gene signature is among the best to classify tumors from both training and validation sets. Kaplan-Meier analyses emphasized its prognostic power both on the whole cohort of patients and on a subgroup with an intermediate risk of recurrence as defined by the St. Gallen criteria. Conclusion: This study identifies a molecular signature specifying a subgroup of patients who do not gain benefits from tamoxifen treatment. These patients may therefore be eligible for alternative endocrine therapies and/or chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.166 · Cited by 566
Cited by
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., Yu, M., Pely, A., Engstrom, A., Zhu, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.013 · Cited by 2,441
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
PrognoScan: a new database for meta-analysis of the prognostic value of genes
Mizuno, H., Kitada, K., Nakai, K., & Sarai, A. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-18 · Cited by 995
Koo, G.-B., Morgan, M. J., Lee, D.-G., Kim, W.-J., Yoon, J.-H., Koo, J. S., Kim, S. I., Kim, S. J., Son, M. K., Hong, S. S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.56 · Cited by 491
Sox2 promotes tamoxifen resistance in breast cancer cells
Piva, M., Domenici, G., Iriondo, O., Rábano, M., Simões, B. M., Comaills, V., Barredo, I., López‐Ruiz, J. A., Zabalza, I., Kypta, R., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303411 · Cited by 328
Metadata
- Authors
- Chanrion, M., Negre, V., Fontaine, H., Salvetat, N., Bibeau, F., Grogan, G. M., Mauriac, L., Katsaros, D., Molina, F., Theillet, C., & Darbon, J.-M.
- Venue
- Clinical Cancer Research
- Published
- 2008-03-15
- Volume
- 14
- Issue
- 6
- Pages
- 1744-1752
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2165319922
- Cited by
- 203
- References
- 2
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1833
- The paper
- Chanrion, M., Negre, V., Fontaine, H., Salvetat, N., Bibeau, F., Grogan, G. M., Mauriac, L., Katsaros, D., Molina, F., Theillet, C., & Darbon, J.-M. (2008). A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1833
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.